Bo Chen, MD
Internal Medicine · New York, NYNPI 1356434104
Payments from drug & device makers
Across 774 payments — averaging $31.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$8K
- Amgen$4K
- AbbVie$3K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$924
- plus $6K from 28 others
What the payments were for
- Consulting fees$2,1009%
- Travel & lodging$650%
- Food & beverage$22,49491%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 180 | $8,082 |
| Amgen(2 entities) | 85 | $3,569 |
| AbbVie(2 entities) | 75 | $2,742 |
| AstraZeneca | 66 | $1,780 |
| Boehringer Ingelheim | 39 | $1,112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 49 | $924 |
| Lilly USA, LLC | 44 | $832 |
| GSK | 25 | $822 |
| Novo Nordisk | 31 | $607 |
| Amarin Pharma, Inc. | 22 | $556 |
| Merck | 24 | $480 |
| Esperion Therapeutics, Inc. | 12 | $457 |
| Bayer | 24 | $398 |
| Pfizer | 16 | $347 |
| Kowa Pharmaceuticals America, Inc. | 15 | $337 |
| Exact Sciences | 8 | $183 |
| Idorsia Pharmaceuticals US Inc | 5 | $174 |
| Madrigal Pharmaceuticals | 2 | $171 |
| Nestle Healthcare Nutrition Inc. | 9 | $154 |
| Phathom Pharmaceuticals, Inc. | 2 | $145 |
| Aimmune Therapeutics, Inc. | 6 | $126 |
| Astellas Pharma US Inc | 6 | $113 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| Seqirus USA Inc | 4 | $75 |
| Sanofi-aventis U.S. LLC | 3 | $74 |
| Genentech USA, Inc. | 4 | $68 |
| IBSA Pharma Inc. | 3 | $53 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Intercept Pharmaceuticals, Inc. | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Ardelyx, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,666 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 598 | $327,279 |
| Diclofenac Epolamine | 429 | $312,541 |
| VemlidyTenofovir Alafenamide | 207 | $297,044 |
| CreonLipase/Protease/Amylase | 130 | $191,198 |
| JardianceEmpagliflozin | 132 | $136,607 |
| FarxigaDapagliflozin Propanediol | 136 | $124,963 |
| JanuviaSitagliptin Phosphate | 134 | $123,395 |
| LinzessLinaclotide | 79 | $58,304 |
| ZenpepLipase/Protease/Amylase | 38 | $54,943 |
| TradjentaLinagliptin | 59 | $54,889 |
| ProliaDenosumab | 26 | $44,429 |
| NexiumEsomeprazole Magnesium | 126 | $43,693 |
| GemtesaVibegron | 80 | $42,690 |
| TrulicityDulaglutide | 28 | $38,482 |
| XareltoRivaroxaban | 48 | $32,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $8,082 | $297,044207 claims |
| AbbVieCreon, Linzess, Restasis | $2,742 | $257,679222 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,112 | $191,495191 claims |
| AstraZenecaFarxiga, Nexium | $1,780 | $168,656262 claims |
| MerckJanuvia, Janumet | $480 | $147,572154 claims |
| Aimmune Therapeutics, Inc.Zenpep | $126 | $54,94338 claims |
| AmgenProlia | $3,569 | $44,42926 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $81 | $42,69080 claims |
| Lilly USA, LLCTrulicity | $832 | $38,48228 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $30,61841 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $924 | $30,32350 claims |
| PfizerEliquis | $347 | $29,63136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.